Despite considerable efforts, only two small molecule drugs targeting chemokine receptors are on the market today: Plerixafor (CXCR4) for stem-cell mobilization (Steinberg and Silva, 2010) and Maraviroc (CCR5) for HIV infection (Woollard and Kanmogne, 2015). The gene discussed is CCR5; the disease is HIV infectious disease.